

RESERVE COPY PATENT SPECIFICATION

NO DRAWINGS

Inventors: CLIFFORD GEORGE POPE and FRANK VALENTINE LINGGOOD

969,772

969,772



Date of filing Complete Specification Dec. 14, 1961.

Application Date Jan. 5, 1961.

No. 508/61.

Complete Specification Published Sept. 16, 1964.

© Crown Copyright 1964.

Index at acceptance:—A5 B8

International Classification:—A 61 k

COMPLETE SPECIFICATION

Toxoids and Their Production

We, THE WELLCOME FOUNDATION LIMITED, of 183—193 Euston Road, London, N.W.1, a company incorporated in England, do hereby declare the invention for which we pray that a patent may be granted to us and the method by which it is to be performed to be particularly described in and by the following statement:—


This invention relates to toxoids derived from toxins of bacterial origin, and to their production.

Protection against several bacterial diseases, such as diphtheria in man and enterotoxaemia in sheep, may be achieved by immunising the host with toxoids derived from the toxins produced by the pathogenic bacteria. The toxoids may be produced by treating the toxins with formaldehyde. Toxoids produced in this way from crude toxin preparations have the disadvantage of not being uniformly antigenic; as soluble toxoids their antigenicity may be low and they are usually combined with an adjuvant, such as an aluminium compound, to give an effective vaccine. On the other hand, the treatment of purified toxins such as purified diphtheria toxin with formaldehyde alone is not satisfactory, because (although the conversion to toxoid may be apparently complete) after the removal of excess of formaldehyde the toxoid may show signs of reversal to a toxic state on dilution and storage.

This invention provides toxoids produced from purified bacterial toxins which are highly antigenic as soluble toxoids and are relatively stable; they are suitable components for vaccines.

The toxoids of this invention are produced by treating a purified bacterial toxin in an aqueous medium with formaldehyde in the presence of an aliphatic diamine of molecular weight below 200 which contains a primary or secondary amino group. Examples of the

aliphatic diamines are lysine (I) and ethylenediamine (II).




The aliphatic diamines must be pharmaceutically acceptable in the amounts likely to be administered to the host during immunisation with these toxoids.



In this invention, it is preferable to use purified bacterial toxin preparations that contain little or none of the nitrogenous material of low molecular weight that may be present initially in crude toxin preparations because much less antigenic toxoids may be produced in the presence of some amines which are not aliphatic diamines. Satisfactory toxoids may, however, be produced by the method of the invention in the presence of mixtures of amines consisting partly of aliphatic diamines and partly of other amines, for example mixtures of lysine and alanine.

The relative proportions of formaldehyde and aliphatic diamine used in this invention may be varied according to the circumstances. When a purified toxin is treated with formaldehyde in the presence of such an amine only, the molar concentration of the latter should preferably be not greater than that of the formaldehyde and may, for example, be between 20% and 100% of that of the formaldehyde,

Although the scope of this invention need not be restricted by any particular theory of its operation, it is thought that the formaldehyde links molecules of the added aliphatic diamine with the toxin molecules (represented in the following formulae as [T].H) by reaction with active hydrogen atoms on amino or other groups reactive with formaldehyde. In the presence of lysine, for example, reaction may occur as follows



The high antigenicity and relative stability of the toxoids of this invention may be associated with the presence in the products of basic side-chains derived in this way from the added aliphatic diamine. Possibly the toxoid produced in treating purified toxins with formaldehyde alone is unsatisfactory because of the reversible formation of reactive hydroxymethyl groups and the linking of toxin molecules.



The invention in another aspect therefore comprises novel toxoids of the formula $[T].CH_2.Y$, in which $[T]$ represents the radical formed by the loss from a bacterial toxin molecule of a hydrogen atom on a group reactive with formaldehyde, and Y represents the radical formed by the loss of a hydrogen atom from an amino group of a molecule of an aliphatic diamine of molecular weight below 200.

For ease of explanation, the toxin molecule $[T].H$ has been shown above as having only one active hydrogen atom, but being a protein molecule it may in fact have many active hydrogen atoms and may be more accurately represented by the formula $[t](H)_n$. The novel toxoids of the invention may therefore contain several radicals $CH_2.Y$ per molecule of toxoid and may be more accurately represented by the formula $[t](CH_2.Y)_n$, Y being as defined above. In these formulae, $[t]$ represents the radical formed from a bacterial toxin molecule by the loss of one or more hydrogen atoms on groups reactive with formaldehyde, and for any particular toxoid molecule n is a positive integer, although it is not necessarily the same integer for all the toxoid molecules in a sample of toxoid and may thus be a non-integral positive number for the sample as a whole.

The following examples illustrate the invention.

EXAMPLE 1

A solution of 27 g. L-lysine monohydrochloride (0.15 mole) (containing 2% D-enantiomer) in 2000 ml. distilled water was treated successively with 15 g. sodium bicarbonate, 15 ml. 36% w/v aqueous formaldehyde solution (0.18 mole) and 600 ml. of an aqueous solution of purified diphtheria toxin containing about 3000 Lf units/ml. and at least 2200 Lf units/mg. protein nitrogen, determined against international standard (flocculation) antitoxin. The mixture was made up to 3000 ml. with distilled water, adjusted

to pH 7.6, and sterilised by filtration; it then contained 570 Lf units/ml.

The mixture was kept at 18—20°C for 3 weeks, and then was at pH 7.1 and contained 560 Lf units/ml. A sample diluted ten-fold in borate buffer was non-toxic to guinea pigs and rabbits on intracutaneous injection. To complete the conversion of toxin into toxoid, the mixture was incubated at 32°C for 3 weeks, and then was at pH 7.25 and contained 540 Lf units/ml., a fall of no significance.

A small volume of the toxoid solution was dialysed against distilled water containing 0.01% sodium *o*-(ethylmercurithio)benzoate, and then tested intracutaneously in rabbits, establishing that the product after removal of formaldehyde was completely non-toxic. The bulk of the toxoid solution was treated with ammonium sulphate and sodium bicarbonate at the rate of 44 g. ammonium sulphate and 0.5 g. sodium bicarbonate per 100 ml. solution, and left overnight. The precipitated toxoid was filtered off and redissolved in about 600 ml. 0.01% aqueous sodium bicarbonate solution and dialysed until free from sulphate.

EXAMPLE 2

A toxoid was prepared by the procedure of Example 1 from purified diphtheria toxin in the presence of 0.05 M-L-lysine 0.05 M-L-alanine and 0.06 M-formaldehyde.

EXAMPLE 3

A toxoid was prepared by the procedure of Example 1 from purified diphtheria toxin in the presence of 0.025 M-L-lysine, 0.075 M-L-alanine and 0.06 M-formaldehyde.

EXAMPLE 4

A 36% w/v aqueous formaldehyde solution was added 5 ml. (0.06 mole) per litre, to a solution of purified diphtheria toxin containing 500 Lf units/ml. in 0.5% w/v aqueous sodium bicarbonate solution. Ethylenediamine was then added 0.1 mole per litre, in small portions, each followed with aqueous hydrochloric acid to prevent the mixture from becoming too alkaline. (Alternatively, the ethylenediamine may be neutralised before addition). The mixture was finally adjusted to pH 7.6 and was kept at 18—20°C for 11 weeks; more formaldehyde (36% w/v aqueous solution), 0.06 mole per litre, was added at 3 weeks, and another 0.06 mole per litre was added at 6 weeks. The mixture was incubated at 32°C for 3 weeks, and then dialysed to remove formaldehyde, giving a solution of satisfactorily antigenic diphtheria toxoid, which remained stable and non-toxic.

EXAMPLE 5

Formaldehyde, 0.06 mole per litre, and

60 ethylenediamine, 0.05 mole per litre, were
 5 added to an aqueous solution of purified
 diphtheria toxin in the manner described in
 Example 4, and the mixture was kept at
 18—20°C for 7 weeks; more formaldehyde,
 0.06 mole per litre, was added at 3 weeks,
 and another 0.012 mole per litre was added
 at 7 weeks. The mixture was incubated at
 32°C for 3 weeks and dialysed to give a
 10 solution of diphtheria toxoid.

EXAMPLE 6

70 Formaldehyde, 0.06 mole per litre, and
 ethylenediamine, 0.0125 mole per litre, were
 added to an aqueous solution of purified
 15 diphtheria toxin in the manner described in
 Example 4, and the mixture was kept at 18—
 20°C for 7 weeks. It was incubated at 32°C
 for 3 weeks and dialysed to give a solution of
 diphtheria toxoid.

VACCINES

20 Sterile injectable aqueous solutions of the
 diphtheria toxoids described in the preced-
 ing examples, in sealed single- or multidose
 containers, may be used as vaccines for the
 prophylaxis of diphtheria. For example, the
 25 toxoid of Example 1 has been incorporated in
 diphtheria vaccine (in particular purified toxoid
 aluminium phosphate), diphtheria-tetanus vac-
 cine and diphtheria-pertussis-tetanus vaccine
 30 of the British Pharmacopoeia. The relative
 stability of the toxoid enables the vaccines of
 this invention to be given a longer shelf life
 than existing vaccines where the stability of the
 diphtheria component is the limiting factor.

WHAT WE CLAIM IS:—

35 1. A method for producing a toxoid from
 a purified bacterial toxin, comprising treating
 the toxin in an aqueous medium with form-
 aldehyde in the presence of an aliphatic di-
 amine of molecular weight below 200 which
 40 contains a primary or secondary amino group.

2. A method claimed in Claim 1 wherein
 the toxin is purified diphtheria toxin.

3. A method claimed in Claim 1 or Claim

2, wherein the molar concentration of the
 aliphatic diamine present is between 20% and
 100% of that of the formaldehyde.

4. A method claimed in Claim 1, Claim 2
 or Claim 3, comprising treating the toxin with
 formaldehyde in the presence of lysine.

5. A method claimed in Claim 1, Claim 2
 or Claim 3, comprising treating the toxin with
 formaldehyde in the presence of ethylene-
 diamine.

6. A method for producing diphtheria
 toxoid from purified diphtheria toxin, sub-
 stantially as described in any one of Examples
 1 to 3.

7. A method for producing diphtheria toxoid
 from purified diphtheria toxin, substantially
 as described in any one of Examples 4 to 6.

8. A toxin produced by the method claimed
 in any preceding claim.

9. A toxoid of the formula $[t](CH_2.Y)_n$, in
 which $[t]$ represents the radical formed from
 a bacterial toxin molecule by the loss of one
 or more hydrogen atoms on groups reactive
 with formaldehyde, Y represents the radical
 formed by the loss of a hydrogen atom from
 an amino group of a molecule of an aliphatic
 diamine of molecular weight below 200, and
 n is a positive number.

10. A toxoid claimed in Claim 9 wherein
 $[t]$ represents the radical formed from a
 diphtheria toxin molecule by the loss of one
 or more hydrogen atoms on groups reactive
 with formaldehyde.

11. A toxoid claimed in Claim 9 or Claim
 10, wherein Y represents the radical formed
 by the loss of a hydrogen atom from an amino
 group of a lysine molecule.

12. A toxoid claimed in Claim 9 or Claim
 10, wherein Y represents the radical formed
 by the loss of a hydrogen atom from an amino
 group of an ethylenediamine molecule.

13. A vaccine containing a toxoid claimed
 in any one of Claims 8 to 12.

R. F. HASLAM

Agent for the Applicants
 Chartered Patent Agent

Leamington Spa: Printed for Her Majesty's Stationery Office by the Courier Press.—1964.
 Published at The Patent Office, 25, Southampton Buildings, London, W.C.2, from which copies may be obtained

ERRATA

SPECIFICATION No. 969,772

Page 1, line 79, for "folliwng" read "follow-
 ing"

Page 2, line 48, for "L-lysine" read
 "L-lysine"

Page 2, lines 49 and 50, for "D-enantiometer"
 read "D-enantiomer"

Page 2, lines 88, 89, 93 and 94, for "M-L-
 lysine" "M-L-alanine" "M-form-
 aldehyde" read "M-L-lysine" "M-L-
 alanine" "M-formaldehyde"

THE PATENT OFFICE
 23rd December 1964